Analyst picks & changes
(AMGN), Thousand Oaks, Calif.
(CEPH), West Chester, Penn.
(CTII), Providence, R.I.
(REGN), Tarrytown, N.Y.
The failure of Amgen-Regeneron Partners'
in Phase III trials for amyotrophic lateral sclerosis (see BioCentury Jan. 13) prompted analysts to revise their outlooks for several companies.
Rodman & Renshaw analyst James Keeney downgraded AMGN to "neutral." While the